Health

Pharma & <u>Biotech</u>

Patrick M.

15:40 Tue 29 Jun 2021

Follow Patrick on:

Graham

view Mindset Pharma Inc

Maxim Group initiates coverage of Mindset Pharma with a 'Buy' rating and price target of US\$1

The analyst noted the company is building out next-generation psychedelics with four families of compounds including psilocybin and DMT/5-MeO-DMT analogues as well as a fifth family platform technology for improving psychedelic drugs

Maxim also pointed out Mindset Pharma has its own proprietary chemical synthesis method for psilocybin and its own compounds



Maxim Group has initiated coverage of Mindset Pharma Inc (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) with a "Buy" rating and a 12-month price target of US\$1.

Mindset Pharma is focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders.

Maxim noted that the company is building out next-generation psychedelics with four families of compounds including psilocybin and DMT/5-MeO-DMT analogues as well as a fifth family platform technology for improving psychedelic drugs.

READ: Mindset Pharma says InterVivo releases first data set for jointly developed Cooperative Psychedelics **Evaluation Platform program**

"Family 1 compounds are the closest to psilocybin, and therefore are likely to have the shortest path to market," Maxim said, adding that the company's first drug candidate MSP-1014 is advancing into Investigational New Drug-enabling studies.

"Families 2-4 are more purpose-designed. Family 2 and Family 4 compounds are likely considerably shorter acting compared to psilocybin, making them more scalable for a macrodose setting," the firm said. "Family 3 is the opposite, longer acting for microdosing, which is more analogous to traditional





<u>Mindset Pharma</u> <u>leading the charge to</u> advance psychedelic <u>medicines to...</u>

Most read

<u>Mining</u>

NEO Battery Materials <u>says latest tests</u> <u>highlight potency of</u> its silicon...

4 days, 7 hours ago

<u>Industry & services</u>

Vicinity Motor approved for stock uplisting to the Nasdaq Capital Market

1 week, 2 days ago

<u>Mining</u>

NA Proactive news <u>snapshot: Bioasis</u> Technologies, Arizona <u>Silveг...</u>

2 days ago

Health

XPhyto Therapeutics signs supply deal to provide 25-min PCR







2 MIN READ





proprietary chemical synthesis method for psilocybin and its own compounds, and has a contract development and manufacturing organization (CDMO) to produce 1 kilogram (kg)

of psilocybin by fiscal year 2021. It said MSP-1014 is easier and

cheaper to manufacture than psilocybin.


"Mindset is differentiated in psychedelics with a fully novel compound strategy, addressing the IP concerns central to the space," the firm said. "MSP-1014 likely has a relatively short path through development, and nextgen purpose designed compounds have the potential to be best-in-class in the longer term."

Mindset's stock recently traded at C\$0.47 in Toronto and at US\$0.35 in New York.

Contact the author: patrick@proactiveinvestors.com

Investor deep dive

Follow him on Twitter @PatrickMGraham



Sign up for Newsletter

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

This record is published on behalf of, which is a paid client of ProactiveInvestors. You understand that ProactiveInvestors receives either monetary or securities compensation for our services, including for...

ProactiveInvectors is a nublisher Volumederstand and arree















recommendation that any particular security,...

FOR OUR FULL DISCLAIMER CLICK HERE

More on this story >



<u>Health</u>

Mindset Pharma says new study data indicates
MSP-1014 is safer and...

2 days, 7 hours ago



<u>Health</u>

Mindset Pharma leading the charge to advance psychedelic medicines...

1 week, 3 days ago



<u>Health</u>

Mindset Pharma's lead therapy shows 'superior efficacy and...

2 days, 8 hours ago



Health

Mindset Pharma and InterVivo release first joint data set focused...

3 weeks, 3 days ago

















Mindset Pharma's lead therapy shows 'superior efficacy and improved safety'...

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo talk to Proactive about the Toronto-based psychedelic medicines-focused group's latest update on the development of its first lead clinical candidate, MSP-1014. Lanthier and...

2 days, 8 hours ago



Mindset Pharma and InterVivo release first joint data set focused...

3 weeks, 3 days ago \Box ಠ≪ೄ 2 MIN READ




Mindset Pharma to move forward with its psilocybin-based compound...

on 3/6/21







proactive 04.53

Health

Mindset Pharma 'excited' by recent, positive findings on its...

on 3/5/21

Mindset Pharma preparing its 'next-gen'

psilocybin for the clinic

on 21/1/21

Editor's picks







>

<u>Energy</u>

<u>Mining</u>

<u>Tech</u>

Trillion Energy says it is benefitting from rising petroleum prices

6 hours, 42 minutes ago

to \$4M to fund exploration <u>at...</u>

8 hours, 5 minutes ago

Standard Uranium to raise up Nextech AR Solutions says subsidiary wins Supporting Associate...

8 hours, 10 minutes ago









Prev article

